jRCT2031210616已完成不适用
A Clinical Pharmacological Study of MT-3921 in Subjects with Human T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Additional screening criteria check may apply for qualification:
- •Subjects aged 20 years or older on the day of consent
- •Subjects with a confirmed diagnosis of HAM according to the diagnostic algorithm of Practical Guideline for HAM 2019 on the day of consent
- •Subjects with an Osame's motor disability score (OMDS) of >=4 and =<6 at Screening and on the first day of the Treatment period (predose)
- •Subjects with no change in OMDS for at least 3 months before the day of consent
- •Subjects with a CSF concentration neopterin of >=6 pmol/mL at Screening
- •Subjects on maintenance oral steroid therapy who have continued to receive the same dose equivalent to =<10 mg/day of prednisolone for at least 3 months before the day of consent
排除标准
- •Additional screening criteria check may apply for qualification:
- •Subjects who have a history of anaphylaxis or clinically significant allergic reactions due to administration of antibody products
- •Subjects exhibiting or with a history of malignant tumor.
- •Subjects with adult T-cell leukemia/lymphoma (ATL) or those with positive HTLV-1 clonality test (Southern blot) at screening and suspected of having ATL
- •Subjects with spinal cord compression lesions, such as cervical spine disease, disc herniation, and ossification of the yellow ligament
- •Subjects with psychiatric disorders, epileptic seizures, or dementia.
- •Subjects with suicide attempts or suicidal ideation corresponding to item 4 or 5 on the Columbia Suicide Rating Scale (C-SSRS) at screening and/or on the first day of the Treatment period (predose)
- •Subjects exhibiting or with a history of hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection.
- •Subjects with the novel Coronavirus disease 2019 (COVID-19)
- •Subjects with severe illness
- •Male or female subjects of childbearing potential who do not agree to use a contraceptive measure from the day of consent to 16 weeks after the last dose of the investigational medical product
- •Female subjects who are pregnant, lactating, or may be pregnant
- •Subjects who have received anti-repulsive guidance molecule (RGM) a antibody containing this investigational medical product
- •Subjects who participated in other clinical studies (including clinical trials) and received drugs (including investigational medical products) or therapy within 12 weeks before the day of consent
研究者
相似试验
已完成
1 期
A Clinical Pharmacological Study of MT-3921 in Subjects with HAMHuman T-cell Leukemia Virus Type 1 (HTLV-1)-Associated Myelopathy (HAM)JPRN-jRCT2031210616Kazuoki Kondou15
已完成
不适用
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesjRCT2031220182Mitsubishi Tanabe Pharma Corporation10
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesAcute Traumatic Cervical Spinal Cord Injury, HTLV-1-Associated Myelopathy (HAM)JPRN-jRCT2031220182Kondo Kazuoki10
已完成
1 期
A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)HTLV-1-Associated Myelopathy (HAM)NCT05240612Mitsubishi Tanabe Pharma Corporation15
已完成
1 期
A Clinical Pharmacology Study of MT-3921 in Healthy Adult MalesHealthy Adult MalesNCT05396235Mitsubishi Tanabe Pharma Corporation10